Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
immuno-oncology
Biotech
Gilead ends phase 3 leukemia trial early after data disappoint
An ad hoc analysis of a phase 3 AML trial found the anti-CD47 antibody is unlikely to improve survival, prompting the Big Biotech to stop the study.
Nick Paul Taylor
Sep 27, 2023 7:48am
AbbVie axes I-Mab pact to exit fast-thinning race for CD47 space
Sep 25, 2023 7:30am
Abpro inks SPAC deal to fund bispecific R&D years after axed IPO
Sep 22, 2023 9:20am
Day One jets off with Sprint's VRK1 program for up to $316M
Aug 16, 2023 10:47am
ALX follows Gilead in axing cancer trials as data disappoint
Aug 11, 2023 9:05am
Sanofi, BioNTech scrap mRNA cancer drug based on early data
Jul 28, 2023 6:53am
